HOME > Investors > Press Releases
2016-01-22
ViroMed Publishes Results from Critical Limb Ischemia (CLI) Phase II Clinical Study
2016-01-21
Texas Heart Institute announces PAD phase II results on "Gene Therapy"
2015-12-04
ViroMed and bluebird bio Enter into License Agreement for Novel Antibodies to Develop Chimeric Antigen Receptor T Cell Therapy
2015-09-01
US FDA Approves VM202 for Phase III Clinical Study of Chronic Non-Healing Ischemic Diabetic Foot Ulcer by US FDA
2015-03-06
A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition
1 2 3 4 5 6 7 8 9 10